FDAnews Device Daily Bulletin
Aug. 6, 2012 | Vol. 9 No. 153
A medical device alleged to melt cellulite should be removed from the market immediately because it poses a significant safety risk and was never cleared by the FDA, patient advocacy group Public Citizen says in a July 18 letter to the FDA.
Makers of hip, knee and shoulder joint implants have two years from July 1, 2012, to apply for their products to be transitioned from Class IIb to Class III devices in Australia, according to the Therapeutic Goods Administration (TGA).
Acacia Research announced Friday that a subsidiary has acquired a patent for intraluminal device technology.
Healthcare products company Covidien said today it has officially opened a new $45 million research and development facility in Shanghai, China.
The Medical College of Wisconsin has begun a clinical study of InTone, a new, FDA-approved medical device that treats female urinary incontinence.
Patients should know their rights if they experience side effects from a medical device.
Boston Scientific has more than 4,500 employees in Ireland but fears that the company may be planning to reduce its footprint here are misplaced, said its CEO who trumpets the “stellar” performance of its Irish operations.
Becton Dickinson said fiscal third-quarter income fell 4.7 percent and unfavorable currency rates will reduce its full-year earnings.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.